SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 396.54 |
| Enterprise Value ($M) | 399.03 |
| Book Value ($M) | -6.90 |
| Book Value / Share | -0.66 |
| Price / Book | -57.43 |
| NCAV ($M) | -11.63 |
| NCAV / Share | -1.11 |
| Price / NCAV | -34.09 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.19 |
| Return on Assets (ROA) | -0.86 |
| Return on Equity (ROE) | -2.71 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.74 |
| Current Ratio | 0.74 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 23.55 |
| Assets | 28.27 |
| Liabilities | 35.18 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -45.08 |
| Net Income | -44.60 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -36.10 |
| Cash from Investing | 35.64 |
| Cash from Financing | -2.82 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Cormorant Asset Management, LP | 19.30 | ||
| 13G | Millennium Management Llc | 5.30 | ||
| 13G | Paradigm Biocapital Advisors LP | 0.00 | -100.00 | |
| 13G/A | K2 HealthVentures Equity Trust LLC | 7.50 | ||
| 13G | Ra Capital Management, L.p. | 4.10 | ||
| 13G | Adage Capital Partners Gp, L.l.c. | 7.70 | ||
| 13G | Integrated Core Strategies (us) Llc | 4.10 | ||
| 13G | Cormorant Global Healthcare Master Fund, LP | 14.27 | ||
| 13G | Point72 Asset Management, L.P. | 8.80 | ||
| 13G | Tang Capital Partners Lp | 9.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 42,138 | 210,961 | 19.97 | |
| 54,673 | 453,891 | 12.05 | |
| 27,389 | 29,753 | 92.05 | |
| 42,761 | 87,144 | 49.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CORT – Corcept Therapeutics Incorporated | COYA – Coya Therapeutics, Inc. |
| CPRX – Catalyst Pharmaceuticals, Inc. | CRDF – Cardiff Oncology, Inc. |
| CRIS – Curis, Inc. |